The invention relates to quinazoline derivatives of formula (I) wherein m is
an integer from 1 to 2; R1 represents hydrogen, hydroxy, halogeno, nitro,
trifluoromethyl, cyano, C1-3alkyl, C1-3alkoxy, C1-3alkylthio,
or NR5R6 (wherein R5 and R6,
which may be the same or different, each represents hydrogen or C1-3alkyl);
R2 represents hydrogen, hydroxy, halogeno, methoxy, amino or nitro;
R3 represents hydroxy, halogeno, C1-3alkyl, C1-3alkoxy,
C1-3alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X1 represents
O, CH2, S, SO,
SO2, NR7CO, CONR8,
SO2NR9, NR10SO2
or NR11 (wherein R7, R8, R9,
R10 and R11 each independently represents hydrogen, C1-3alkyl
or C1-3alkoxyC2-3alkyl); R4 represents an optionally
substituted 5 or 6 membered saturated carbocyclic or heterocyclic group or a group
which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may
contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry
a terminal optionally substituted group selected from alkyl and a 5 or 6 membered
saturated carbocyclic or heterocyclic group, and salts thereof; processes for their
preparation, pharmaceutical compostions containing a compound of formula (I) or
a pharmaceutically acceptable salt thereof as active ingredient. The compounds
of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects
of VEGP, a property of value in the treatment of a number of disease states including
cancer and rheumatoid arthritis.
##STR1##
